Cg-0416

Phase 1

HHongKong Curegene Innovation Co., Limited

Cg-0416 is one of 3 therapeutic programs targeting Overweight and Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight and ObesityNot yet recruiting

Overweight and ObesityPhase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Overweight and Obesity

#DrugCompanyPhaseTrials

AZD9550

AstraZeneca

Preclinical

1 2

LAE102 IV

LLaekna Limited

Phase 1

1 3

Cg-0416

HHongKong Curegene Innovation Co., Limited

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Overweight and Obesity

NCT07724431

Clinical

Trials by Indication[1]

Overweight and Obesity1 trial

A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

Not yet recruiting·HHongKong Curegene Innovation Co., Limited·Phase 1·NCT07724431·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cg-0416. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cg-0416. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — HongKong Curegene Innovation Co., Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHongKong Curegene Innovation Co., Limited

Cg-0416

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News